Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150mg ibandronate with once-weekly oral administration of 70mg alendronate in postmenopausal osteoporosis - non-inferiority trial.

Trial Profile

Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150mg ibandronate with once-weekly oral administration of 70mg alendronate in postmenopausal osteoporosis - non-inferiority trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Alendronic acid; Ibandronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MOTION
  • Most Recent Events

    • 01 Jan 2008 Results have been published.
    • 19 Sep 2007 Primary endpoint reported by GlaxoSmithKline.
    • 19 Sep 2007 Tolerability data reported at ASBMR 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top